MOMA Therapeutics

Executive Summary

MOMA Therapeutics is a precision oncology company focused on targeting molecular machines, specifically ATPase enzymes, which are critical for cancer cell survival. Leveraging its proprietary platform, the company aims to develop small-molecule inhibitors that disrupt the functional mechanisms of these essential proteins, addressing a broad class of dependencies across multiple cancer types. Founded in 2020 and headquartered in Cambridge, MA, MOMA has raised $600 million in total funding, reflecting strong investor confidence in its innovative approach. The company's platform enables systematic identification and validation of ATPase targets, potentially unlocking novel therapeutic avenues for cancers with high unmet need. Currently at the preclinical stage, MOMA is advancing a pipeline of ATPase inhibitors toward clinical development. The company's substantial financial backing positions it well to progress its lead programs through IND-enabling studies and into first-in-human trials. Key near-term milestones include the selection of development candidates, initiation of IND-enabling toxicology studies, and potential presentation of preclinical proof-of-concept data at major oncology conferences. While still early-stage, MOMA's differentiated platform and significant funding support a conviction that the company could become a leader in targeting ATPase-driven cancers.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Program40% success
• Q2 2026Preclinical Data Presentation at Major Conference (e.g., AACR)70% success
• Q4 2026Series C or Next Financing Round60% success